NOV 11, 2015 06:00 AM PST

A Comprehensive Toxicology Screening Solution Targeted to Individual Needs

C.E. CREDITS: CE
Speakers
  • Director of Clinical Chemistry, Houston Methodist Hospital, Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College
    Biography
      Dr. Ping Wang is currently the Medical Director of Clinical Chemistry at Houston Methodist Hospital and Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. She is also Director of the ComACC-accredited Postdoctoral Fellowship Program at Houston Methodist Hospital. Dr. Wang was trained at Tsinghua University, University of Wisconsin-Madison and UCSF. She is board certified in Clinical Chemistry, Molecular Diagnostics and Toxicological Chemistry by American Board of Clinical Chemistry, for which she currently serves as Vice President and Chair of Examination Committee. She is a fellow of the National Academy of Clinical Biochemistry. She currently serves or had served on the boards of NACCCA, AACC LVDD division and TDM and Toxicology division. Dr. Wang has received many honors and awards including the Career Cornerstone Award, NACB Distinguished Abstract Award and AACC Outstanding Research Award. She has published over 60 peer-reviewed papers, abstracts and book chapters. Dr. Wang has over 10 years of experience directing and managing high complexity CLIA clinical laboratories, and is an expert in CLIA regulations, laboratory management to drive clinical efficiency, quality and outcome, clinical assay development, optimization and execution in a highly regulated environment. Besides clinical service and teaching, Dr. Wang's current research interests focus on translating novel research and start-up findings into clinical diagnostic tools. She is Principle Investigator of two NIH grants, and actively collaborates with major diagnostic companies as well as start-up ventures to develop next-generation diagnostic tools.

    Abstract:

    Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline different reasons for which the provider want clinical toxicology testing, and describe a comprehensive solution using both immunoassays and LC tandem mass spectrometry to target individual needs. The speaker will also discuss the performance details of the LC tandem mass spectrometry method. After completing this activity, the learner will be able to describe several clinical needs for toxicology testing. They will also be able to describe a comprehensive solution for clinical toxicology screening, targeted to these individual needs.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    Loading Comments...